Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 3, 2002, Pages 985-992

  Johnell, Olof ^a   Scheele, Wim H ^b   Lu, Yili ^b   Reginster, Jean Yves ^c   Need, Allan G ^d   Seeman, Ego ^e  

^a Universiteitssjukhuset MAS ^*  (Sweden)

^b ELI LILLY AND COMPANY   (United States)

^c CHU Brull   (Belgium)

^d INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^e AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CREATININE; OSTEOCALCIN; RALOXIFENE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; THORAX PAIN; VASODILATATION;

EID: 0036963450     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.3.8325     Document Type: Article

References (30)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 348:1535-1541
2. Cummings S, Black D, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082
3. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
4. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut 3rd CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
5. Chesnut 3rd CH, Silverman SL, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109:267-276
6. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
7. Wimalawansa SJ 1998 A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104:219-226
8. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A 2000 Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 85:720-726
9. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA 1999 Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84:3076-3081
10. Fleisch H 1998 Bisphosphonates: mechanisms of action. Endocr Rev 19:80-100
11. Mitlak BH, Cohen FJ 1999 Selective estrogen receptor modulators: a look ahead. Drugs 57:653-663
12. Johnston Jr CC, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath 3rd H, Gennari C, Christiansen C, Arnaud CD, Delmas PD 2000 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women: three-year data from two double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444-3450
13. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451
14. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW 2000 The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85:214-218
15. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK 2000 A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95:95-103
16. Fugere P, Scheele WH, Shah A, Strack TR, Glant MD, Jolly E 2000 Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 182:568-574
17. Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman ME, Lo SC, Walls EL, Zeng J 2001 Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 93:51-56
18. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
19. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL 1998 Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747-1754
20. Chesnut III CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher V, Pryor-Tillotson S, Santora II AC 1995 Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152
21. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs Jr RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora II AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
22. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB 1999 Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 2:323-342
23. Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett Jr AH, Baylink DJ, Crusan CE, Chines AA 2001 Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86:1890-1897
24. Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG 2000 A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 85:2197-2202
25. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P 1998 Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 128:253-261
26. Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH 1997 Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 12:6-15
27. Flora L, Hassing GS, Cloyd GG, Bevan JA, Parfitt AM, Villanueva AR 1981 The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res 3:289-300
28. Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 27:13-20
29. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620
30. Greendale GA, Wells B, Marcus R, Barrett-Connor E 2000 How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 160:3065-3071